Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Oncoinvent Advances Radspherin[®] to Second Dose Level in Ongoing Phase 1 Clinical Trial

Safety review of first dose-level cohort allows progression to second cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin[®] clinical trial.Oslo 4. September 2020  Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies announced today that the trial Safety Monitoring Committee overseeing the first-in-human Phase 1 clinical study of Radspherin[®] in colorectal cancer patients suffering from peritoneal carcinomatosis have approved the advancement of the study to the second level dosing cohort. Jan A.

Improved market conditions for pyrolysis oil could strongly increase revenues from Enviro’s plants

Over the past year, Scandinavian Enviro Systems AB (publ, “Enviro” or “the Company”) has noticed a dramatic increase in interest in the oil—known as pyrolysis oil—that the company can extract from end-of-life tyres using its proprietary technology. The oil has a high bio content due to the natural rubber in tyres, and in the company’s opinion is therefore of great interest to many players in the market because it could replace fossil-based alternatives. “Based on the market response and our own calculations, we judge that the oil recovered from end-of-life tyres could contribute to a

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

Announcement no. 35 - 4 September 2020 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, Motortramp A/S continuously sells shares pro rata and the market is to be informed accordingly – see the attached file. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information: Martin Badsted, CFO, tel.: +45 3315 0451Anne-Louise Dam-Rasmussen, Head of Communications, tel.: +45 3273 0624

Paulig intends to make a 45-million EUR investment in the Tex Mex production in Belgium

Paulig aims to strengthen its position as a market leader of Tex Mex in Europe with a 45-million EUR investment into a new production facility in Roeselare, Belgium. The new factory, which would be built next to the existing facilities, will focus on producing tortillas and increase the company’s innovation capabilities. Paulig expects to start production in the new factory in spring 2022. “This investment marks an important step in the execution of our international growth strategy. It is the biggest investment Paulig has made outside Finland and will strengthen our leading

Karin Hedlund new Head of IT at Axfood

Karin Hedlund will be the new Head of IT at Axfood with responsibility for the Axfood Group’s IT operations and strategy as well as the company’s extensive IT development plan.Most recently, Karin Hedlund served as Head of IT (CIO) at Lantmännen for more than seven years. Prior to her role at Lantmännen, she held leading positions at Ericsson and Accenture with a focus on IT and business development within the food retail sector and telecom, as well as different board positions. Karin is familiar with Axfood as she during seven years after the turn of the millennium was development manager

Risk Intelligence A/S appoints new Chief Commercial Officer, as part of the future-facing commercial organisation

Risk Intelligence A/S (“Risk Intelligence” or "the Company") announces today that the company has appointed the current Sales Director Jim Pascoe as new Chief Commercial Officer to head the new commercial organisation.As part of a new commercial plan that optimises the organisation, Risk Intelligence has promoted Sales Director Jim Pascoe as new Chief Commercial Officer. In this position, Jim Pascoe gets the full responsibility to re-configure, optimise, and invigorate the commercial side in the Company including sales and marketing, client relations and retention.   Building on the

BioStock: CombiGene gears up in epilepsy project

Yesterday, CombiGene announced the signing of a production agreement with the Spanish gene therapy manufacturer Viralgen for the production of the drug candidate CG01. The choice of partner is based on the fact that Viralgen can manufacture the candidate on a large scale, which means both cost savings and faster development of CG01, a gene therapy developed for the treatment of patients with drug-resistant focal epilepsy.Read the full article about CombiGene at biostock.se: https://www.biostock.se/en/combigene-gears-up-in-epilepsy-project/ This is a press release from BioStock -

US ARMY 2nd SFAB expands capability with new portable Intercom system from INVISIO

The US Army 2nd Security Force Assistance Brigade (SFAB) will add the new lightweight and portable Intercom system from INVISIO to their capabilities to enable instant deployment into any military or commercial passenger vehicle or platform. Following testing the SFAB has now placed an initial order for delivery in the second half of 2020. The order value does not exceed SEK 5 million. INVISIO’s Intercom system will provide the US Army 2nd Security Force Assistance Brigade with seamless integration of all communication sources such as radios or devices, as well as a unique inter-team

Alligator Bioscience presents positive biomarker data demonstrating proof of mechanism in mitazalimab clinical Phase I study

Lund, Sweden, September 4, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today biomarker data from a recently performed clinical Phase I study of the drug candidate mitazalimab, its wholly owned CD40 antibody in development primarily for the treatment of pancreatic cancer. The data will be presented today at the scientific conference PEGS: The Essential Protein Engineering Summit being held virtually August 31- September 4, 2020. “The presented biomarker data confirm the proof of mechanism and strengthen our belief in mitazalimab as a powerful therapeutic agent. The

Members of the Shareholders' Nomination Board of Tikkurila

Tikkurila Oyj, Stock Exchange Release, 4 September 2020 at 9:30 a.m. (EEST) Members of the Shareholders' Nomination Board of Tikkurila The Shareholders' Nomination Board of Tikkurila Oyj has been appointed. The members of the Nomination Board are: · Annika Paasikivi, President & CEO (Oras Invest Ltd) · Hanna Kaskela, Director, Responsible investment (Varma Mutual Pension Insurance Company) · Patrick Lapveteläinen, CIO (Sampo Group), Chairman of the Board of Directors (Mandatum Life) · Expert member of the Nomination Board: Jari Paasikivi, Chairman of the Board of

BioStock: Cyxone is looking forward to an eventful autumn

When Tara Heitner came in as new CEO for the Malmö-based biotech company Cyxone, it marked the start of an increase in activity within the company. Shortly after she took office in June, they announced filing of new patents, recruited new scientific advisors, a head of development and established a new collaboration within a new therapeutic area. The news got the share price increasing by more than 40 per cent during summer and has ignited expectations on further value enhancing events to come.Read the full article about Cyxone at biostock.se: https://www.biostock.se/2020/09/cyxone-ser-

Sectra’s three-month interim report 2020/2021: Strong growth in order bookings and cash flow begins the fiscal year

Linköping, Sweden, September 4, 2020 – International medical imaging IT and cybersecurity company Sectra’s  (STO: SECT B) highest priority is to help customers give patients the best possible care and to protect critical infrastructure and communication where society is the most vulnerable. Demand for the company’s services and products remained high during the first quarter and order bookings more than doubled compared with the year-earlier period. Aside from the typical seasonal effects, sales and profit were affected by the ongoing pandemic. With a strong

Elisa’s Earnings Releases and AGM in 2021

ELISA STOCK EXCHANGE RELEASE 4 SEPTEMBER 2020 AT 9:00 AMIn 2021 Elisa will publish its financial results statement, half year financial report and interim reports as follows: · 28 January 2021: Financial results for 2020 · 21 April 2021: Interim report Q1 2021 · 16 July 2021: Half year financial report 2021 · 20 October 2021: Interim report Q3 2021 Elisa's Annual General Meeting is planned to be held on 8 April 2021.  ELISA CORPORATION Vesa SahivirtaIR Director+358 50 520 5555 Distribution: Nasdaq HelsinkiPrincipal Mediaelisa.com 

AcadeMedia grows the number of children and students by approximately five percent organically

Preliminary figures show that the number of children and students in AcadeMedia’s three school segments will increase by approximately five percent in the first quarter of 2020/21 compared with the corresponding period last year. Early measurements indicate that the average number of children and students at AcadeMedia’s preschools and schools will reach just over 85,500 (81,468) during the first quarter. Growth in all three segments is purely organic. The figures are preliminary. AcadeMedia’s preschools grow with approximately three percent through new establishments Early

Herantis Pharma Plc Announces Appointment of Investor Relations Team

Herantis Pharma PlcCompany release September 4, 2020 at 9:00 AM Eastern European Summer Time Herantis Pharma Plc (“Herantis” or “Company”) announced today that the company has appointed Julie Silber and Gabriela Urquilla of JG Investor Relations AB (“JG-IR”) as the new Investor Relations team, as of 1 September 2020.   JG-IR is a Swedish based financial and healthcare communications firm with a strong track record supporting successful Nordic listed companies to help establish best-in-class investor relations and expand their exposure with key audiences in Nordic and global capital

Herantis Pharma to Host a Webinar on the Cerebral Dopamine Neurotrophic Factor (CDNF) Phase I-II Data Readout

Herantis Pharma Plc (“Herantis” or “Company”) will be hosting a webinar to share more details on CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months .Herantis Pharma PlcCompany release September 4, 2020 at 9:00 AM Eastern European Summer Time Event Details: CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months Date and Time: September 15, 2020 at 15:00 – 16:00 CET

Jouni T. Laine appointed EVP for Food Solutions unit to be established at HKScan

HKScan Corporation, Stock Exchange Release, 4 September 2020 at 9:00 Finnish timeJouni T. Laine appointed EVP for Food Solutions unit to be established at HKScan Jouni T. Laine (56) has been appointed EVP for a new Food Solutions unit to be established at HKScan and a member of the Group Executive Team. Laine will join HKScan from the CEO position at the Clewer Group, part of Salmela-Yhtiöt. He will take up his new role no later than 1 January 2021, when the new Food Solutions unit starts.  The key task of the Food Solutions unit is to contribute to HKScan's strategic target to grow

Scandi Standard strengthens its Group Management with strategic Supply Chain Director

Scandi Standard has decided to strengthen the capabilities and focus on its Supply Chain management and has therefore created the new senior position Group Supply Chain Director. Recruited for the new position is Michael Budtz Berthelsen who joined the company in the beginning of September, as previously communicated in the report for the second quarter. Scandi Standard is on a growth journey. The company has through strategic projects identified significant potential in optimizing the entire process from egg to finished products on the consumer’s plate. To address the potential, a new

Thailand rated among the best golfing destinations for golfers around the world

  Indian golfers have rated Thailand among the best golfing destinations in a recent survey jointly conducted by the Tourism Authority of Thailand (TAT) New Delhi Office and India-based golf management company, Sports and Leisure Worldwide (SLW). Mr. Vachirachai Sirisumpan, Director of the TAT New Delhi Office, said, “We conducted the survey to ascertain the impact of COVID-19 on golf tourism to Thailand and were happy to see the enthusiasm to travel for golf among the Indian golfers.” A whopping 97% of Indian golfers who took part in the “Golfing in Thailand” survey rated

ZICCUM AB submits patent applications for improved operation of the LaminarPace system for commercial vaccine production

Ziccum's LaminarPace system for the production of temperature-stable vaccines is already protected by approved patents. However, during ongoing work to further develop and prepare LaminarPace for commercial production, a number of new, innovative solutions have been developed. By submitting two more patent applications for central design elements Ziccum intends to strengthen and extend the protection of the company's unique production method.Ziccum CEO Göran Conradson: "We are further expanding our Intellectual Property portfolio around LaminarPace, including key details that are important

Q-linea installs the first ASTar system at Uppsala University Hospital

Q-linea AB (publ) (OMX: QLINEA), today announced that an ASTar® instrument is now being used for beta testing at Uppsala University Hospital and that the hospital will participate in the company's European pivotal clinical study.Following this spring's collaboration with the laboratory for clinical microbiology at Uppsala University Hospital, Q-linea has now installed an ASTar instrument for evaluation at the hospital for the upcoming pivotal clinical study. “It is an important step for us that ASTar now will be evaluated in a real laboratory environment by a potential customer. Uppsala

Polygiene takes first steps with Dr. Scholl’s

Dr. Scholl’s[®], the most trusted brand in foot care, is now teaming up with odor-controlling specialist Polygiene to keep its premium insoles fresh from odor and microbes. Moving forward, Dr. Scholl’s[® ]insoles will combine two Polygiene technologies – antibacterial Stays Fresh Technology and Odor Crunch[®] treatment – to stop the growth of odor-causing bacteria. “We are looking forward to elevating the value proposition of our hardest working insole with the addition of Polygiene technology.” says Kate Godbout, SVP of Marketing at Dr. Scholl’s[®].The first product to

Oncopeptides completes the extended enrollment for the pivotal phase 3 OCEAN study in relapsed refractory multiple myeloma – 495 patients included

STOCKHOLM — September 4, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the last patient has been successfully enrolled in the pivotal phase 3 study OCEAN in relapsed refractory multiple myeloma (RRMM). The original enrollment target of 450 patients was reached in May 2020, but an analysis indicated that patients were staying longer on treatment than initially estimated. Thus, a decision was made to leave recruitment open to ensure that the number of disease progression events needed to complete the study would be reached within a reasonable timeframe. An

IP-Only Enterprise becomes GlobalConnect

The Swedish B2B provider of fiber based data communication services, IP-Only Enterprise, changes its name to GlobalConnect, creating a unified B2B brand across the GlobalConnect group.  IP-Only’s fiber-to-the-home consumer business, will continue operating under the IP-Only brand in Sweden. The name change will be implemented on September 21, 2020.On November 21, 2019 the plan to merge GlobalConnect and Swedish IP-Only was announced. By February 3, 2020 GlobalConnect and IP-Only began operating as one joint company, becoming a leading digital infrastructure provider across Northern Europe,

There are no items matching the current filter
There are no more items matching the current filter
Back to top